Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate

Abstract Background The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration‐resistant prostate cancer (mCRPC). The majority of mCRPC patients are elderly suffering from chronic...

Полное описание

Библиографические подробности

Главные авторы:	Ondřej Fiala, Petr Hošek, Hana Korunková, Milan Hora, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti, Jindřich Fínek
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2024-01-01
Серии:	Cancer Medicine
Предметы:	abiraterone acetate angiotensin‐converting enzyme inhibitors antihypertensives castration‐resistant prostate cancer comedication enzalutamide
Online-ссылка:	https://doi.org/10.1002/cam4.6853
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!